Pfizer Ventures and Chiesi Ventures returned to back inherited disease therapy developer 4D Molecular Therapeutics, which filed to go public in September.
US-based gene medicine developer 4D Molecular Therapeutics (4DMT) completed a $75m series C round yesterday featuring Chiesi Ventures and Pfizer Ventures, subsidiaries of pharmaceutical firms Chiesi Group and Pfizer.
The round was led by healthcare-focused hedge fund manager Viking Global Investors and included financial services group MiraeAsset and Berkeley Catalyst Fund, a venture unit aligned with University of California.
Cystic Fibrosis Foundation, Amzak Health, Longevity Vision Fund, BVF Partners, Arrowmark Partners, Ridgeback Capital Investments, Perceptive Advisors, Pappas Capital, Casdin Capital,…
